What is the typical first-line pharmacologic therapy for Parkinson disease and its mechanism?

• A. Pramipexole; stimulates dopamine receptors
• B. Rasagiline; MAO-B inhibitor
• C. Levodopa-carbidopa; levodopa is converted to dopamine in brain; carbidopa prevents peripheral conversion
• D. Benztropine; anticholinergic

Answer: (C)

Replenishing brain dopamine with a precursor that can cross into the brain, boosted by blocking its peripheral breakdown, is the most effective initial approach for Parkinson disease. Levodopa, the dopamine precursor, crosses the blood-brain barrier and is converted to dopamine in the brain, directly addressing the deficit that drives motor symptoms like bradykinesia and rigidity. Pairing it with carbidopa, a peripheral decarboxylase inhibitor, prevents most of the levodopa from being converted to dopamine outside the brain. This increases the amount reaching the brain and reduces peripheral side effects such as nausea and vomiting, making the treatment both more effective and better tolerated. Over time, patients may experience motor fluctuations and dyskinesias, necessitating careful dosing adjustments or schedules.

Other options exist but aren’t typically first-line for most patients. Dopamine agonists can help, especially to delay levodopa therapy in younger individuals or to manage fluctuations, but they’re generally less potent for motor symptoms. MAO-B inhibitors slow dopamine breakdown and may be used as early add-ons or monotherapy in milder disease. Anticholinergics like benztropine can help tremor but have cognitive side effects, limiting their use, especially in older patients.